Essai Clinique

Généré le 30 avr. 2024 à partir de

Titre	Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
Protocole ID	EMERGE 402 (JZP712-402)
ClinicalTrials.gov ID	NCT04894591
Type(s) de cancer	Poumon à petites cellules
Phase	Phase IV
Stade	Maladie avancée ou métastatique
Type étude	Autre
Médicament	Zepzelca
Institution	CISSS DE CHAUDIERE-APPALACHES HOTEL-DIEU DE LEVIS 143 rue Wolfe, Lévis, QC, G6V 3Z1
Ville	
Investigateur principal	Dre Danièle Marceau
Coordonnateur	Pierre Bédard 418-835-7121
Statut	Actif en recrutement
But étude	To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Critères d'éligibilité	• Patient has initiated or will be receiving Zepzelca treatment in line with the local Zepzelca prescribing information. • Decision to initiate treatment with Zepzelca was made as per investigator's routine treatment practice prior to enrollment in the study. • Patient, or a legally acceptable representative, signed the informed consent before any study-related activities are undertaken.
Critères d'exclusion	• Patients who discontinued a prior Zepzelca treatment due to adverse events. • Patient who received more than 2 cycles of Zepzelca treatment in their current treatment schedule. • Patient received treatment with any investigational agent within 30 days prior to first Zepzelca infusion or plans to use another investigational agent while receiving Zepzelca.